Dabigatran: how the drug company withheld important analyses

Dabigatran: how the drug company withheld important analyses
BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g4670 (Published 23 July 2014)
Cite this as: BMJ 2014;349:g4670

“In an investigation by The BMJ Deborah Cohen finds that recommendations for use of new generation oral anticoagulants may be flawed because regulators did not see evidence showing that monitoring drug plasma levels could improve safety”

[Full text at Journal Web site]
[Full Text PDF at Journal Web site]
[PubMed]

[EMLitOfNote Commentary]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s